CytoMed Therapeutics Limited (GDTC)

NASDAQ: GDTC · Real-Time Price · USD

Compare

2.430

-0.250 (-9.33%)

At close: Oct 23, 2025, 4:00 PM EDT

2.310

-0.120 (-4.94%)

After-hours: Oct 23, 2025, 7:18 PM EDT

CytoMed Therapeutics Stock Forecast

Stock Price Forecast

There is currently no analyst price target forecast available for CytoMed Therapeutics.

Price Target: $ (0.00%)

Analyst Consensus: n/a

Target	Low	Average	Median	High
Price	n/a	n/a	n/a	n/a
Change	n/a	n/a	n/a	n/a

Analyst Ratings

There are currently no analyst ratings available for CytoMed Therapeutics.

Recommendation Trends

Rating	Jun '24	Jul '24	Aug '24	Sep '24
Strong Buy	0	0	0	0
Buy	1	1	1	1
Hold	0	0	0	0
Sell	0	0	0	0
Strong Sell	0	0	0	0
Total	1	1	1	1

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Bruce Jackson Benchmark	Benchmark	Buy Reiterates $5	Buy	Reiterates	$5	+105.76%	Oct 10, 2024
Bruce Jackson Benchmark	Benchmark	Buy Reiterates $5	Buy	Reiterates	$5	+105.76%	Jun 11, 2024
Bruce Jackson Benchmark	Benchmark	Buy Reiterates $5	Buy	Reiterates	$5	+105.76%	Dec 4, 2023
Bruce Jackson Benchmark	Benchmark	Buy Initiates $5	Buy	Initiates	$5	+105.76%	Jul 21, 2023

More Analyst Ratings

Financial Forecast

Revenue This Year

530.40K

from 503.37K

5.37%

from 503.37K

Revenue Next Year

n/a

from 530.40K

EPS This Year

-0.17

from -0.22

EPS Next Year

n/a

from -0.17

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025
Revenue	59.47K	113.84K	363.91K	507.74K	503.37K	530.40K
Revenue Growth	-	91.43%	219.67%	39.52%	-0.86%	5.37%
EPS	-0.33	-0.30	-0.40	-0.39	-0.22	-0.17
EPS Growth	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-
No. Analysts	-	-	-	-	-	3

Financial currency is SGD. Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025
High	546,000
Avg	530,400
Low	509,600

Revenue Growth

Revenue Growth	2025
High	8.5%
Avg	5.4%
Low	1.2%

EPS Forecast

EPS	2025
High	-0.18
Avg	-0.17
Low	-0.17

EPS Growth

EPS Growth	2025
High	-
Avg	-
Low	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.